Finn Søndergaard – CEO, Intsel Chimos, France
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
Intsel Chimos is an independent French laboratory with a long history of expertise in the import of medicines for patients in a therapeutic impasse and a partner of choice for hospitals. In 2010 and 2011, Intsel Chimos obtained orphan drug status from the EMA and the FDA respectively for a molecule intended for the treatment of gliomas (brain tumours), which marks the beginning of their transformation into a promising biotech player in France.
Contact
162 Bureaux de la Colline • 92213 SAINT CLOUD CEDEX • France
Tel: 01 49 11 66 80
Web: intselchimos.com
Email: contact@intselchimos.com
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
Mr. Finn Søndergaard, CEO of Intsel Chimos, an independent French laboratory with a long history of expertise in the import of medicines for patients in a therapeutic impasse, highlights Intsel…
ALK’s Denis Delval reveals how France is number one in terms of volumes for the group and number two in terms of revenues, just behind Germany; how the four Danes…
The president and CEO of AREVA Med, the medical subsidiary of AREVA Group, the biggest nuclear company in the world, discusses the circumstances that inspired AREVA’s foray into nuclear medicine,…
The President of CEPS, the French pricing agency, reveals the issues around the launch of the hepatitis C drug Sovaldi in 2014 and of CEPS´ role to ensure that innovative products are available to all…
The President of Innothera talks about their unique business model, being in both the drug production and compression stockings businesses, how almost 95 percent of their drug production is exported,…
Olivier Pilley, French GM of the Swiss-American biotech company with a pioneering computational approach to anti-cancer therapies, presents ARIAD’s fascinating R&D model, his optimistic assessment of the competitiveness of the French…
The Director of the Social Security talks about the need to strengthen the sustainability of the French social security system, how France is attached to its unique system combining a…
The head of Aspen sterile operations and managing director of Aspen NDB, reveals how their facility in France acts as the main platform for the group´s sterile business, a market…
The CEO of Diaxonhit Group, a fully integrated French leader in in vitro diagnostics, discusses the company’s strategic focus on specialty vitro diagnostics, his perspective on the challenge of consolidation…
The Vice President of Health and Medicine at Pierre and Marie Curie University (UPMC) and Director of the University’s Institute of Oncology reveals how the French social security system needs…
The Director of the CNCR and the person in charge of the industrial sector, talk about the fragmented nature of French clinical research funding, why when it comes to boosting…
The President of France’s Association for CROs (AFCROs) discusses the issues surrounding France’s clinical research sector and the actions that both the public and private sector need to take to…
The president of Gedeon Richter France and CEO of PregLem, a Swiss-based biotech company acquired by Gedeon Richter in 2010, discusses the exciting synergies that have emerged from this partnership…
See our Cookie Privacy Policy Here
